Evaluation of two yellow fever vaccines for routine immunization programs in Argentina

Human Vaccines

Volumn 4, Issue 2, 2008, Pages 121-126

  Ripoll, Carlos ^a   Ponce, Amalia ^b   Wilson, Mario M ^c   Sharif, Norma ^b   Vides, José B ^b   Armoni, Judith ^d   Teuwen, Dirk E ^e  

^a Ministerio de Salud   (Argentina)

^b Hospital Oscar Orias   (Argentina)

^c Ministerio de Salud y Ambiente   (Argentina)

^d Sanofi Pasteur   (Argentina)

^e SANOFI PASTEUR   (France)

Author keywords

Adverse events; Argentina; Safety; Yellow fever; Yellow fever vaccine

Indexed keywords

STAMARIL; YELLOW FEVER VACCINE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ARGENTINA; ARTHRALGIA; ARTICLE; ASTHENIA; CHILD; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SCREENING; EMPORIATRICS; FAINTNESS; FEMALE; FLU LIKE SYNDROME; HEALTH PROGRAM; HUMAN; HYPOTENSION; IMMUNIZATION; INFANT; INFECTION PREVENTION; INJECTION SITE BLEEDING; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE SWELLING; LIMB PAIN; MALE; MYALGIA; NAUSEA; NEWBORN; PRURITUS; RHINITIS; SYSTEMIC DISEASE; UNSPECIFIED SIDE EFFECT; URTICARIA; VACCINATION; VOMITING; YELLOW FEVER;

EID: 45849111057     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.4.2.5216     Document Type: Article

References (29)

1. World Health Organization. Yellow fever situation in Africa and South America, 2005. Wkly Epidemiol Rec 2006; 81:317-24.
2. Bryant JE, Holmes EC, Barrett ADT. Out of Africa : A molecular perspective on the introduction of yellow fever virus into the Americas. PLoS Pathog 2007; 3:0668-73.
3. Monath TP, Cetron MS. Prevention of yellow fever in persons traveling to the tropics. Clin Infect Dis 2002; 34:1369-78.
4. Russell M, Barwick Eidex R, Hayes E, Marfin A, Monath T, Teuwen D, Ranney M, Cetron M. Travelers' Health: Yellow Book. Prevention of specific infectious diseases: Yellow fever. http://www2.ncid.cdc.gov/travel/yb/utils/ybGet.asp? section=dis&obj=yellowfever.htm. Accessed 11 June 2007.
5. TM yellow fever vaccine. Expert Rev Vaccines 2004; 3:413-20.
6. Barrett ADT, Monath TP, Barban V, Niedrig M, Teuwen DE. 17D Yellow Fever Vaccines: New Insights, A report of a Workshop held during the World Congress on Medicine and Health in the Tropics, Marseille, France, Monday 12 September 2005. Vaccine 2007; 25:2758-65.
7. World Health Organization. Yellow fever vaccine. Wkly Epidemiol Rec 2003; 78:349-59.
8. th edition. Philadelphia:Saunders, 2004; 1095-176.
9. Huarcaya WV, Paredes CEM, Saldan̄a EON, Villarroel OT. Serie Análisis de la Situación de Salud del Perú-2005. Ministerio de Salud del Perú 2006. Available at http://www.oge.sld. pe/publicaciones/pub_asis/asis15.pdf. Accessed 2 July 2007.
10. Codeço CT, Luz CJ, Struchiner CJ. Risk assessment of yellow fever urbanization in Rio de Janeiro, Brazil. Trans Roy Soc Trop Med Hyg 2004; 98:702-10.
11. Gubler DJ. Resurgent vector-borne diseases as a global health problem. Emerg Infect Dis 1998; 4:442-50.
12. Petersen LR, Marfin AA. Shifting epidemiology of Flaviviridae. J Travel Med 2005; 12:S3-11.
13. Massad E, Burattini MN, Coutinho FA, Lopez LF. Dengue and the risk of urban yellow fever reintroduction in São Paulo State, Brazil. Rev Saude Publica 2003; 37:477-84.
14. Camacho LA, Freire Mda S, Leal Mda L, Aguiar SG, Nascimento JP, Iguchi T, Lozana Jde A, Farias RH; Collaborative Group for the Study of Yellow Fever Vaccines. Immunogenicity of WHO-17D and Brazilian 17DD yellow fever vaccines: a randomized trial. Rev Saude Publica 2004; 38:671-8.
15. TM and YF-VAX®) in healthy infants and children in Peru. Am J Trop Med Hyg 2005; 72:189-97.
16. Monath TP, Nichols R, Archambaulr WT, WT, Moore L, Marchesani R, Tian J, Shope RE, Thomas N, Schrader R, Furby D, Bedford P. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial. Am J Trop Med Hyg 2002; 66:533-41.
17. Camacho LAB, Gomes de Aguiar S, Freire MS, Leal Mda L, do Nascimento JP, Iguchi T, Lozana JA, Farias RH; Collaborative Group for the Study of Yellow Fever Vaccines. Reactogenicity of yellow fever vaccines in a placebo controlled trial. Rev Saúde Pública 2005; 39:413-20.
18. Martin M, Tsai TF, Cropp B, Chang GJ, Holmes DA, Tseng J, Shieh W, Zaki SR, Al-Sanouri I, Cutrona AF, Ray G, Weld LH, Cetron MS. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet 2001; 358:98-104.
19. Vasconcelos PF, Luna EJ, Galler R, Silva LJ, Coimbra TL, Barros VL, Monath TP, Rodigues SG, Laval C, Costa ZG, Vilela MF, Santos CL, Papaiordanou PM, Alves VA, Andrade LD, Sato HK, Rosa ES, Froguas GB, Lacava E, Almeida LM, Cruz AC, Rocco IM, Santos RT, Oliva OF; Brazilian Yellow Fever Vaccine Evaluation Group. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet 2001; 358:91-7.
20. Chan RC, Penney DJ, Little D, Carter IW, Roberts JA, Rawlinson WD. Hepatitis and death following vaccination with 17D-204 yellow fever vaccine. Lancet 2001; 358:121-2.
21. Khromava AY, Eidex RB, Weld LH, Kohl KS, Bradshaw RD, Chen RT, Cetron MS and The Yellow Fever Vaccine Safety Working Group. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine 2005; 23:3256-63.
22. Galler R, Pugachev KV, Santos CLS, Ocran SW, Jabor AV, Rodrigues SG, Marchevsky RS, Freire MS, Almeida LF, Cruz AC, Yamamura AM, Rocco IM, da Rosa ES, Souza LT, Vasconcelos PF, Guirakhoo F, Monath TP Phenotypic and molecular analyses of yellow fever 17DD vaccine viruses associated with serious adverse events in Brazil. Virology 2001; 290:309-19.
23. Barban V, Girerd Y, Aguirre M, Gulia S, Petiard F, Riou P, Barrere B, Lang J. High stability of yellow fever 17D-204 vaccine: a 12-year retrospective analysis of large-scale production. Vaccine 2007; 25:2941-50.
24. Camacho LAB, Gomes de Aguiar S, Freire MS, Leal Mda L, do Nascimento JP, Iguchi T, Lozana JA, Farias RH; Collaborative Group for the Study of Yellow Fever Vaccines. Reactogenicity of yellow fever vaccines in a placebo controlled trial. Rev Saúde Pública 2005; 39:413-20.
25. World Health Organization. Yellow fever situation in Africa and South America. Wkly Epidemiol Rec. 2006; 81:317-24.
26. Suzano CES, Amaral E, Sato HK, Papaiordanou PM, Campinas Group of Yellow Fever Immunization during Pregnancy. The effects of yellow fever immunization (17DD) inadvertently used in early pregnancy during a mass campaign in Brazil. Vaccine 2006; 24:1421-6.
27. Cavalcanti DP, Salomāo MA, Lopez-Camelo J, Pessoto MA, Campinas Group of Yellow Fever Immunization during Pregnancy. Early exposure to yellow fever vaccine during pregnancy. Trop Med Int Health 2007; 12:833-7.
28. World Health Organization. Yellow fever. Fact sheet 100. 2001. Available at: http://www.who.int/. Accessed June 29, 2007.
29. Barrett ADT. Current status of Flavivirus vaccines. Ann NY Acad Sci 2001; 951:262-71.